<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274999</url>
  </required_header>
  <id_info>
    <org_study_id>OCUN-020</org_study_id>
    <nct_id>NCT03274999</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use</brief_title>
  <official_title>Randomized, Controlled, Single-Center, Cross-Over Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the change in tear meniscus height (TMH) produced by intranasal
      stimulation with TrueTear compared with the same device applied extranasally (control).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on interim review and decision to re-design the study.
  </why_stopped>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Actual">November 9, 2017</completion_date>
  <primary_completion_date type="Actual">November 9, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in change in tear meniscus height</measure>
    <time_frame>From Day 0 to Day 14 (±11 days)</time_frame>
    <description>Difference in change in tear meniscus height (immediately post application compared to pre-application) in the analysis eye between the intranasal and control applications.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>TrueTear Intranasal Application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal application of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TrueTear Extranasal Application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extranasal application (control) of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueTear Intranasal Application</intervention_name>
    <description>Intranasal application of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)</description>
    <arm_group_label>TrueTear Intranasal Application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueTear Extranasal Application</intervention_name>
    <description>Extranasal application (control) of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)</description>
    <arm_group_label>TrueTear Extranasal Application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline Ocular Surface Disease Index© (OSDI©) score of at least 23 with no more than
             three responses of &quot;not applicable&quot;

          -  In at least one eye, a baseline Schirmer test of ≤ 10 mm/5 minutes AND a cotton swab
             nasal stimulation Schirmer test of at least 7 mm higher in the same eye

        Exclusion Criteria:

          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that may
             increase the risk of bleeding

          -  History of nasal or sinus surgery

          -  Vascularized polyp, deviated septum or severe nasal airway obstruction at the
             Screening visit

          -  Intraocular and extraocular surgery in either eye within three months of the Screening
             Visit or refractive surgery within twelve months of the Screening Visit

          -  Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic
             or active implanted electronic device in the head
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Guillon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>mguillon@otg.co.uk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ocular Technology Group International</name>
      <address>
        <city>London</city>
        <zip>SW1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>For information to locate a study location near you, please visit AllerganClinicalTrials.com</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

